Biogen posts Q3 2026 earnings beat and lifts full‑year adjusted EPS guidance

Biogen reported third‑quarter 2026 revenue of $2.8 billion, up about 11% year over year, and adjusted earnings of $2.62 per share, beating analyst estimates. The results were driven by strong sales of recent products such as Spinraza, Leqembi, Syfovre, Skyclarys and Empaveli, the latter two coming from the recent Apellis acquisition. The company raised the lower end of its full‑year adjusted EPS outlook to a range of $12.20‑$13.00 per share.

The raised EPS floor improves Biogen’s earnings outlook for 2026, giving investors a clearer target for profitability. The guidance lift also signals confidence in the growth portfolio that now accounts for roughly two‑thirds of revenue.

  • 1Q3 2026 revenue was $2.8 billion, up 11% YoY (reported basis).
  • 2Adjusted EPS for the quarter was $2.62, beating consensus.
  • 3Full‑year 2026 adjusted EPS guidance was raised to $12.20‑$13.00 per share.
  • 4Growth‑portfolio revenue rose 49% YoY to $1.26 billion, representing 63% of core pharma revenue.
  • 5Apellis‑acquired products Syfovre and Empaveli generated $191.3 million and $51.5 million respectively, the first full quarter of results.
  • 6Adjusted R&D expenses increased 31% YoY to $567.1 million; adjusted SG&A rose 23% YoY to $729.7 million.
  • Some materials (e.g., source 14) state a tightened adjusted EPS guidance of $15.95‑$16.75, conflicting with the $12.20‑$13.00 range reported in other sources.

Sources